Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma

Area of Science:

• Oncology
• Pharmacogenomics
• Molecular Biology

Background:

• Primary liver cancers, including hepatocellular carcinoma and cholangiocarcinoma, are a significant global health burden.
• Poor patient prognosis is often linked to intrinsic or acquired chemoresistance in cancer cells.
• Mechanisms of chemoresistance involve genetic alterations affecting drug targets, metabolism, and cellular pathways.

Purpose of the Study:

• To review the role of germline and somatic mutations in liver cancer chemoresistance.
• To explore how these mutations impact drug transporters, metabolic enzymes, organelles, and signaling molecules.
• To highlight the need for comprehensive pharmacogenomic studies to improve liver cancer treatment.

Main Methods:

• Literature review of existing research on liver cancer chemoresistance.
• Analysis of genetic alterations (mutations, polymorphisms, spliced variants) in key cellular components.
• Synthesis of information on the functional consequences of these alterations on drug response.

Main Results:

• Germline and somatic mutations significantly contribute to liver cancer chemoresistance.
• Altered genes affect drug transporters, drug-metabolizing enzymes, and cellular signaling pathways.
• These genetic changes lead to reduced drug efficacy, altered molecular targets, and modified tumor microenvironments.

Conclusions:

• Genetic mutations are central to the complex mechanisms of liver cancer chemoresistance.
• A deeper understanding of these mutations is crucial for developing effective pharmacogenomic strategies.
• Further research is needed to personalize treatment and improve outcomes for liver cancer patients.